Application of BNP, Hcy, AVP, CPT in disease development and efficacy evaluation of patients with chronic pulmonary heart disease

doi:10.3969/j.issn.1004-583X.2021.07.004

Abstract

Abstract:

Objective To investigate the value of brain natriuretic peptide(BNP), homocysteine(Hcy), arginine vasopressin(AVP), and copeptin(CPT) in disesae development and efficacy evaluation of patients with chronic pulmonary heart disease(CPHD).Methods Totally 80 CPHD patients, including 42 in remission stage and 38 in exacerbation phase were enrolled from January 2020 to January 2021, 60 patients without CPHD, who came to our hospital for a physical examination at the same time, were served as control group. BNP, Hcy, AVP, CPT of all patients were obtained. Low flow oxygen, clear airway, and heart failure control as well as other therapies were performed in CPHD patients, and BNP, Hcy, AVP, CPT of those 80 CPHD patients were recorded before and after treatment.Results BNP, Hcy, AVP, CPT of CPHD patients were significantly higher than those of without CPHD patients. Before treatment for CPHD patients, BNP, Hcy, AVP, CPT in exacerbation phase were higher than those in remission stage (P<0.05), but they were significant decrease in all CPHD patients after treatment, while the items were still higher in exacerbation phase than in remission stage (P<0.05).Conclusion Compared with those without CPHD, BNP, Hcy, AVP, CPT of CPHD patients were significantly higher with disease development, strengthened inspection will be beneficial to CPHD patients.

Key words: pulmonary heart disease, brain natriuretic peptide, homocysteine, arginine vasopressin, copeptin

CLC Number:

R541.5

Wei Qingyuan, Yin Xufang, Li Jiaojiao. Application of BNP, Hcy, AVP, CPT in disease development and efficacy evaluation of patients with chronic pulmonary heart disease[J]. Clinical Focus, 2021, 36(7): 600-603.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.07.004

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I7/600

Figures/Tables 2

References 16

[1]	崔紫阳, 刘聪辉, 王红阳, 等. 慢性肺源性心脏病急性加重期患者血浆骨膜蛋白、内皮素-1、N端脑钠肽前体的表达及意义[J]. 中国循证心血管医学杂志, 2019,11(1):51-54.
[2]	Haw A, Shah R, Strachan P. Progression of pulmonary alveolar microlithiasis to pulmonary hypertension and cor pulmonale[J]. Chest, 2019,156(4):1847-1848.
[3]	孔华玮. 肺心病急性加重期患者脑钠肽(BNP)水平与凝血功能的相关性及意义[J]. 血栓与止血学, 2020,26(5):101-102.
[4]	刘燕, 施胜铭, 胡先全, 等. 血清BNP, HCY及Hs-CRP在肺心病患者病情评估中的临床意义[J]. 心脑血管病防治, 2020, 20(2):45-47+73.
[5]	胡诗礼, 李丽华, 张李, 等. 血清IL-17和CHE及和肽素水平与老年 COPD合并肺部感染的相关性[J]. 中华医院感染学杂志, 2020,30(21):82-86.
[6]	Hammond JD. Proteins of serum and oedema fluid in anoxic cor pulmonale[J]. Lancet (London, England), 2019,1(7169):136-138.
[7]	周雨田, 李小惠, 陈果, 等. 慢性肺源性心脏病急性发病中的PTX-3水平变化的研究[J]. 成都医学院学报, 2019, 14(2):211-213+217.
[8]	苏军, 张艳丽. 补肺益气汤联合穴位贴敷对肺气亏虚型肺心病缓解期患者心肺功能及血管内皮功能的影响[J]. 现代中西医结合杂志, 2020,29(26):58-62.
[9]	徐亮, 李燕妮, 殷云杰, 等. 心电向量图联合血浆脑钠肽及HbAlc检测对慢性肺心病的诊断价值[J]. 重庆医学, 2019,48(4):673-675.
[10]	Kagiyama N, Kitai T, Hayashida A, et al. Prognostic value of bnp reduction during hospitalization in patients with acute heart failure[J]. J Card Fail, 2019,25(9):712-721. doi: 10.1016/j.cardfail.2019.04.004 URL
[11]	李丽, 李慧, 梁蔚繁, 等. 血清同型半胱氨酸检测在老年慢性阻塞性肺病合并心力衰竭患者中应用价值研究[J]. 临床军医杂志, 2020,48(10):1233-1234.
[12]	Jiang Y, Liu F, Li Q, et al. The correlation of serum Cys-C and HCY levels and intracranial vascular atherosclerotic stenosis in patients with acute ischaemic stroke[J]. Acta Medica Mediterranea, 2020,36(3):1987-1991.
[13]	占长河, 岑燕谊, 林蓉朱. 益气强心饮对慢性心衰大鼠血AVP水平及水潴留影响[J]. 四川中医, 2019,37(1):57-59.
[14]	李军锋, 梁晶. 口服托伐普坦对急性失代偿性心力衰竭合并低钠血症的疗效及安全性研究[J]. 中国药物与临床, 2019,19(8):1349-1350.
[15]	赵智东, 付会文, 崔利锋, 等. NT-proBNP与凝血功能, 动脉血气分析对慢性肺心病急性加重期患者判断价值分析[J]. 中国实验诊断学, 2020,24(12):8-12.
[16]	申岩, 高瑞敏, 康玲玲, 等. 不同程度CHF患者血浆BNP、和肽素水平变化及其与心功能分级的相关性[J]. 心血管康复医学杂志, 2019,28(5):583-586.

组别	例数	性别(例)		年龄 (岁)	BMI (kg/m²)
组别	例数	男	女	年龄 (岁)	BMI (kg/m²)
对照组	60	29	31	63.95±7.75	23.52±4.52
肺心病缓解期组	42	25	17	62.29±7.83	23.75±4.60
肺心病急性加重期组	38	27	11	63.98±7.74	23.50±4.55
χ²/F值		1.166		0.680	0.404
P值		0.280		0.508	0.960

组别	例数	性别(例)		年龄 (岁)	BMI (kg/m²)
组别	例数	男	女	年龄 (岁)	BMI (kg/m²)
对照组	60	29	31	63.95±7.75	23.52±4.52
肺心病缓解期组	42	25	17	62.29±7.83	23.75±4.60
肺心病急性加重期组	38	27	11	63.98±7.74	23.50±4.55
χ²/F值		1.166		0.680	0.404
P值		0.280		0.508	0.960

组别	例数	BNP(pg/mL)		Hcy(μmol/L)		AVP(ng/L)		CPT(ng/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	60	67.90±11.25	-	13.40±4.15	-	4.25±0.5	-	2.8±0.5	-
肺心病缓解期组	42	265.50±38.80	120.30±28.50^△	19.40±6.80	14.30±4.50^△	54.50±4.50	20.50±4.15^△	7.5±0.8	5.2±0.5^△
肺心病急性加重期组	38	470.15±105.25	191.20±33.50^*#△	28.35±8.12	18.20±5.15^*#△	130.50±8.50	35.65±8.25^*#△	13.0±1.5	7.3±0.7^*#△
F值		545.556	10.224	66.574	3.615	7220.932	10.525	1343.555	15.550
P值		<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01

组别	例数	BNP(pg/mL)		Hcy(μmol/L)		AVP(ng/L)		CPT(ng/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	60	67.90±11.25	-	13.40±4.15	-	4.25±0.5	-	2.8±0.5	-
肺心病缓解期组	42	265.50±38.80	120.30±28.50^△	19.40±6.80	14.30±4.50^△	54.50±4.50	20.50±4.15^△	7.5±0.8	5.2±0.5^△
肺心病急性加重期组	38	470.15±105.25	191.20±33.50^*#△	28.35±8.12	18.20±5.15^*#△	130.50±8.50	35.65±8.25^*#△	13.0±1.5	7.3±0.7^*#△
F值		545.556	10.224	66.574	3.615	7220.932	10.525	1343.555	15.550
P值		<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01